Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)
P. Saiag, R. Gutzmer, P. A. Ascierto, M. Maio, J.-J. Grob, et al.. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). Annals of Oncology, 2016, 27, pp.1947 - 1953. ⟨10.1093/annonc/mdw291⟩. ⟨inserm-01407384⟩